Embase webinar

24/05/2017

Aim of this webinar

The aim of this webinar is to give you a better understanding of Embase indexing tools and rules and how to make use of Emtree to get the best results out of Embase

I will be showing you:

- How we index a typical article using Emtree
- How Emtree is built-up and managed
- How drugs, diseases and devices are indexed in Embase

What is Embase indexing?

Indexing facilitates consistent and comprehensive retrieval of information from Embase, significantly enhancing search options which would otherwise be limited to citation and abstract only

http://supportcontent.elsevier.com/Support%20Hub/Embase/Files%20&%20Attachements/4683-Embase%20indexing%20guide%202015.pdf

Embase is a highly versatile, multipurpose and up-to-date biomedical database. It covers the most important international biomedical literature from 1947 to the present day and all articles are indexed in depth using Elsevier's Life Science thesaurus Embase Indexing and Emtree®. The entire database is also conveniently available on multiple platforms.



Agenda

- How a typical article is indexed
- Emtree: controlled vocabulary for Embase indexing and searching
- Emtree content
- Synonyms for taxonomy-supported searching
- Polyhierarchy for taxonomy-supported searching
- Check tags
- Emtree updates & management
- Make use of Emtree to get the best results out of Embase

How a typical article is indexed

What is Embase indexing?

Contents lists available at SciVerse ScienceDirect

Pulmonary Pharmacology & Therapeutics

journal homepage: www.elsevier.com/locate/ypupt

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

D. Singh [a,*], H. Magnussen [b], A. Kirsten [b], S. Mindt [c], C. Caracta [d], B. Seoane [e], D. Jarreta [e], E. Garcia Gil [e]

[a] University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, Langley Building, Southmoor Road, Manchester M23 9QZ, UK
[b] Pulmonary Research Institute at Hospital Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany
[c] Klinische Forschung Hamburg GmbH, Hoheluftchaussee 18, 20253 Hamburg, Germany
[d] Forest Research Institute, Harborside Financial Center, Jersey City, NJ 07311, USA
[e] Almirall R&D Centre, Ronda General Mitre 151, 08022 Barcelona, Spain

ARTICLE INFO

Article history:
Received 14 December 2011
Received in revised form
27 March 2012
Accepted 29 March 2012

Keywords:
Aclidinium
Bronchodilation
COPD
Phase II
Twice-daily

ABSTRACT

This Phase IIb, double-blind, double-dummy, placebo- and active-comparator-controlled crossover study (ClinicalTrials.gov identifier: NCT01120093) assessed efficacy and safety of three doses of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease. Patients were randomised to one of five treatment sequences each consisting of twice-daily (BID) aclidinium 100 μg, 200 μg, 400 μg (via Genuair®*), formoterol 12 μg (via Aerolizer®) and matched placebo for 7 days, with a 5- to 9-day washout period. Primary endpoint was mean change from baseline in forced expiratory volume in 1 s (FEV_1) normalised area under the curve $(AUC)_{0-12}$ on Day 7. Secondary endpoints were: change from baseline in FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24} and morning pre-dose FEV_1 on Day 7. Adverse events were monitored throughout the study. Of 79 randomised patients, 68 (86.1%) completed the study. After 7 days of treatment, aclidinium and formoterol produced statistically significantly greater changes from baseline in FEV_1 normalised AUC_{0-12} vs placebo ($p < 0.0001$). FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24}, and morning pre-dose FEV_1 were also statistically significantly greater with all aclidinium doses vs placebo ($p < 0.0001$). Improvements in primary and

Contents lists available at SciVerse ScienceDirect

Pulmonary Pharmacology & Therapeutics

journal homepage: www.elsevier.com/locate/ypupt

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

D. Singh [a,*], H. Magnussen [b], A. Kirsten [b], S. Mindt [c], C. Caracta [d], B. Seoane [e], D. Jarreta [e], E. Garcia Gil [e]

[a] University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, Langley Building, Southmoor Road, Manchester M23 9QZ, UK
[b] Pulmonary Research Institute at Hospital Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany
[c] Klinische Forschung Hamburg GmbH, Hoheluftchaussee 18, 20253 Hamburg, Germany
[d] Forest Research Institute, Harborside Financial Center, Jersey City, NJ 07311, USA
[e] Almirall R&D Centre, Ronda General Mitre 151, 08022 Barcelona, Spain

ARTICLE INFO

Article history:
Received 14 December 2011
Received in revised form
27 March 2012
Accepted 29 March 2012

Keywords:
Aclidinium
Bronchodilation
COPD
Phase II
Twice-daily

ABSTRACT

This Phase IIb, double-blind, double-dummy, placebo- and active-comparator-controlled crossover study (ClinicalTrials.gov identifier: NCT01120093) assessed efficacy and safety of three doses of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease. Patients were randomised to one of five treatment sequences each consisting of twice-daily (BID) aclidinium 100 μg, 200 μg, 400 μg (via Genuair®*), formoterol 12 μg (via Aerolizer®) and matched placebo for 7 days, with a 5- to 9-day washout period. Primary endpoint was mean change from baseline in forced expiratory volume in 1 s (FEV_1) normalised area under the curve $(AUC)_{0-12}$ on Day 7. Secondary endpoints were: change from baseline in FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24} and morning pre-dose FEV_1 on Day 7. Adverse events were monitored throughout the study. Of 79 randomised patients, 68 (86.1%) completed the study. After 7 days of treatment, aclidinium and formoterol produced statistically significantly greater changes from baseline in FEV_1 normalised AUC_{0-12} vs placebo ($p < 0.0001$). FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24}, and morning pre-dose FEV_1 were also statistically significantly greater with all aclidinium doses vs placebo ($p < 0.0001$). Improvements in primary and

Embase indexing

The article full-text is read to extract significant concepts

The purpose of this Phase IIb study was to assess the bronchodilatory effects of three doses of aclidinium (100 μg, 200 μg and 400 μg) BID in patients with moderate to severe COPD compared with placebo to guide dose selection for additional Phase III studies. The long-acting β_2-agonist (LABA) formoterol (12 μg BID) was used as an active comparator, so that the profile of aclidinium BID could be compared to a BID bronchodilator that is currently used in clinical practice.

2. Methods

2.1. Study subjects

Patients aged ≥40 years with a clinical diagnosis of stable moderate to severe COPD according to the current guidelines [8] were enrolled in the study. At screening, patients were required to have a post-salbutamol forced expiratory volume in 1 s (FEV_1)/forced vital capacity (FVC) ratio <70%, a post-salbutamol FEV_1 ≥30% and <80% of the predicted normal value, and be current or former cigarette smokers of ≥10 pack-years. Patients with a history or current diagnosis of asthma, with any respiratory tract infection or who had experienced a COPD exacerbation in the 6 weeks prior to screening (3 months if it resulted in hospitalisation) were excluded. Other exclusion criteria were: other clinically significant respiratory or cardiovascular conditions, and contraindications for anticholinergic drugs.

2.2. Study design

This was a double-blind, double-dummy, placebo- and active-comparator-controlled crossover study in patients with COPD (ClinicalTrial.gov identifier: NCT01120093) conducted in 11 centres in Germany and Belgium. Following a screening visit, eligible patients underwent a 14-day run-in period prior to randomisation. Patients were randomised to one of five 7-day treatment sequences (separated by 5- to 9-day washout periods) using a 5 × 5 Latin square crossover design [9]. Treatments were aclidinium 100 μg, 200 μg, 400 μg BID (via Genuair®*, Almirall, Barcelona, Spain) and formoterol 12 μg (via Foradil Aerolizer®, Novartis AG, Basel, Switzerland) and matched placebo. The Genuair®* inhaler is a novel multidose, breath-actuated dry powder inhaler (DPI) that generates a highly reproducible mean fine particle dose and delivers aclidinium effectively to lungs over a range of inhalation flows [10,11]. Genuair®* incorporates multiple feedback mechanisms to ensure that doses are administered correctly, including a colour window changing from green to red and an audible click [10]. The Aerolizer® inhaler is a single-dose, breath-actuated DPI, which also performs consistently in terms of dosing efficiency [12]. But the feedback to the patient on whether the dose has been administered successfully is based on the single-dose, capsule-based nature of this inhaler [12].

Patients received the morning and evening dose 12 h apart for 7 consecutive days and were assessed on Days 1 and 7 of each treatment period. Salbutamol (100 μg per puff), as-needed, was allowed during the run-in and after randomisation. Inhaled glucocorticosteroids, oral and parenteral glucocorticosteroids (up to 10 mg/day), and oral sustained-release theophyllines were permitted if their use was stable ≥4 weeks prior to screening. Tiotropium was stopped at least 72 h prior to screening and LABAs glucocorticosteroids or resulted in hospitalisation.

This study was conducted according to International Conference on Harmonization/Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by local institutional review boards and ethics committees (Ethikkomission Schleswig-Holstein, Segeberg, Germany; Commissie voor Medische Ethiek, Universitair Ziekenhuis Gent, Belgium). All patients provided written informed consent prior to the study.

2.3. Assessments

2.3.1. Efficacy

At screening, spirometry measurements were taken at two intervals (1 h apart) prior to the morning dose, and then at 0.5, 1, 2, 3, 4 and 6 h post-morning dose on Day 1. On Day 7, measurements were taken at the same times as Day 1 and also at 8, 10, 12 (pre-evening dose), 13, 14, 15, 16, 22, 23 and 24 h post-morning dose. Spirometers and all necessary equipment were provided by a centralised company (CareFusion) for specific use in this study. Spirometers were calibrated every day of use and after maintenance; instrument recommendations were followed to ensure accurate and comparable spirometric data. Spirometry assessments were performed in triplicate, and all three measurements were required to meet acceptability and repeatability criteria according to current recommendations [13]. If either of these criteria were not met, additional measurements (up to a maximum of eight) were taken until the criteria were met. Baseline was defined as the mean of the two pre-dose spirometry measurements on Day 1 of each treatment period. The use of relief medication was recorded in patient diary cards. Convenience of use of both inhaler devices was assessed at the end of the study using a seven-item questionnaire.

2.3.2. Safety

Adverse events (AEs) were monitored throughout the study and were graded as mild, moderate or severe. AEs were considered treatment-emergent (TEAEs) if they started on or after the first dose of study drug, or if the severity of a medical condition worsened after study drug. Other safety investigations included 12-lead electrocardiogram (ECG, performed both pre-dose and 2-h post-dose), blood-pressure measurements, and assessments of clinical laboratory parameters and vital signs.

2.4. Endpoints

The primary efficacy variable was mean change from baseline in FEV_1 normalised area under the curve (AUC) for the 12-h period immediately after morning dose (AUC_{0-12}) on Day 7. Secondary efficacy endpoints included: change from baseline in FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24}, and morning pre-dose (trough) FEV_1 at Day 7. Additional efficacy endpoints included: change from baseline in FVC normalised AUC_{0-12}, AUC_{12-24} and AUC_{0-24} at Day 7; change from baseline in morning peak FEV_1 on Day 1 and Day 7; morning trough FVC on Day 7; and change from baseline in the use of relief medication after 7 days of treatment (baseline was assessed as relief medication use during the run-in period).

Safety and tolerability endpoints included AEs and change from baseline in blood pressure, ECG, laboratory parameters and vital signs.

Embase indexing

The article full-text is read to extract significant concepts

Table 4
Treatment-emergent adverse events reported by ≥2 patients in any treatment group (safety population).

	Number (%) of patients reporting adverse events				
	Placebo	Aclidinium			Formoterol
		100 µg	200 µg	400 µg	12 µg
	N = 76	*N* = 73	*N* = 73	*N* = 74	*N* = 74
Any TEAE	16 (21.1)	11 (15.1)	13 (17.8)	14 (18.9)	11 (14.9)
Any severe TEAE	1 (1.3)	0 (0)	2 (2.7)	2 (2.7)	1 (1.4)
Headache	5 (6.6)	4 (5.5)	4 (5.5)	5 (6.8)	2 (2.7)
Nasopharyngitis	1 (1.3)	0 (0)	0 (0)	3 (4.1)	1 (1.4)
Toothache	0 (0)	1 (1.4)	0 (0)	2 (2.7)	0 (0)
Cough	2 (2.6)	1 (1.4)	1 (1.4)	1 (1.4)	1 (1.4)
Pruritus	2 (2.6)	1 (1.4)	1 (1.4)	0 (0)	2 (2.7)
Diarrhoea	2 (2.6)	1 (1.4)	1 (1.4)	0 (0)	0 (0)

SAE, serious adverse event; TEAE, treatment-emergent adverse event.

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

Singh D., Magnussen H., Kirsten A., Mindt S., Caracta C., Seoane B., Jarreta D., Garcia Gil E.

Pulmonary Pharmacology and Therapeutics 2012 **25:3** (248-253)

Go to publisher for the full text

Abstract

This Phase IIb, double-blind, double-dummy, placebo- and active-comparator-controlled crossover study (ClinicalTrials.gov identifier: NCT01120093) assessed efficacy and safety of three doses of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease. Patients were randomised to one of five treatment sequences each consisting of twice-daily (BID) aclidinium 100 µg, 200 µg, 400 µg (via Genuair®*), formoterol 12 µg (via Aerolizer®) and matched placebo for 7 days, with a 5- to 9-day washout period. Primary endpoint was mean change from baseline in forced expiratory volume in 1 s (FEV_1) normalised area under the curve (AUC_{0-12} on Day 7. Secondary endpoints were: change from baseline in FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24} and morning pre-dose FEV_1 on Day 7. Adverse events were monitored throughout the study. Of 79 randomised patients, 68 (86.1%) completed the study. After 7 days of treatment, aclidinium and formoterol produced statistically significantly greater changes from baseline in FEV_1 normalised AUC_{0-12} vs placebo ($p < 0.0001$). FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24}, and morning pre-dose FEV_1 were also statistically significantly greater with all aclidinium doses vs placebo ($p < 0.0001$). Improvements in primary and secondary endpoints were statistically significantly greater with aclidinium 400 µg vs 100 µg. The safety profile of aclidinium was comparable to placebo. These results demonstrated that twice-daily aclidinium produced dose-dependent clinically meaningful improvements in FEV_1 compared with placebo. This study also confirmed the use of an aclidinium BID dosing regimen and established aclidinium 200 µg and 400 µg as suitable doses for further investigation in Phase III trials. © 2012 Elsevier Ltd.

Drug Terms

open all drug terms

aclidinium bromide, formoterol fumarate, placebo, salbutamol

Disease Terms

open all disease terms

chronic obstructive lung disease, coughing, diarrhea, ECG abnormality, headache, pruritus, rhinopharyngitis, side effect, tooth pain

Device Terms

powder inhaler

Other Terms

adult, article, bronchodilatation, controlled study, crossover procedure, disease severity, double blind procedure, drug dose comparison, drug dose regimen, drug effect, drug monitoring, drug safety, evening dosage, female, forced expiratory volume, forced vital capacity, human, laboratory test, major clinical study, male, morning dosage, multicenter study, phase 2 clinical trial, priority journal, randomized controlled trial

Author Keywords

Aclidinium, AE, AUC, BID, Bronchodilation, COPD, DPI, ECG, FEV_1, FVC, ITT, LABA, LAMA, LS, Phase II, SAE, SE, TEAE, Twice-daily

Correspondence Address

Singh D. ✉: University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester Langley Building, Southmoor Road, Manchester M23 9QZ, United Kingdom.

Author Addresses

Singh D. ✉: University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester Langley Building, Southmoor Road, Manchester M23 9QZ, United Kingdom.
Magnussen H. ✉, **Kirsten A.** ✉: Pulmonary Research Institute at Hospital Grosshansdorf Woehrendamm 80, D-22927 Grosshansdorf, Germany.
Mindt S. ✉: Klinische Forschung Hamburg GmbH Hoheluftchaussee 18, 20253 Hamburg, Germany.

Embase index (overview)

Drug Terms open all drug terms

aclidinium bromide, formoterol fumarate, placebo, salbutamol

Disease Terms open all disease terms

chronic obstructive lung disease, coughing, diarrhea, ECG abnormality, headache, pruritus, rhinopharyngitis, side effect, tooth pain

Device Terms

powder inhaler

Other Terms

adult, article, bronchodilatation, controlled study, crossover procedure, disease severity, double blind procedure, drug dose comparison, drug dose regimen, drug effect, drug monitoring, drug safety, evening dosage, female, forced expiratory volume, forced vital capacity, human, laboratory test, major clinical study, male, morning dosage, multicenter study, phase 2 clinical trial, priority journal, randomized controlled trial

Device Tradenames	Aerolizer (Novartis, Switzerland), Genuair (Almirall, Spain)
Drug Tradenames	foradil (Novartis, Switzerland)
Device Manufacturers	Almirall (Spain), Novartis (Switzerland)
Drug Manufacturers	Novartis (Switzerland)
CAS Registry Numbers	aclidinium bromide (320345-99-1) formoterol fumarate (43229-80-7) salbutamol (18559-94-9, 35763-26-9)
Clinical Trial Numbers	ClinicalTrials.gov (NCT01120093)

Embase indexing principles



1. EXTRACT relevant information

In assigning index terms, indexers check the full article (not just title and abstract). All concepts with significant information are indexed

2. EXPAND by giving context

Index terms are controlled by the Emtree thesaurus, resulting in consistent coverage of concepts that may be expressed in many different ways in the literature

3. FOCUS by applying guidelines

Indexing is carried out according to well-defined guidelines (summarized in the Indexing Guide), which further enhances the consistency of the database

Emtree

Controlled vocabulary for Embase indexing and searching

Emtree provides the controlled vocabulary for indexing

Content

- Terminology that can be used to index
- Focus on drugs, almost 32,500 terms: generics, trade names and chemical names
- Medical devices: 3,350 devices and counting

Structure

- Faceted structure
- Term types
- Natural language, synonym-rich
- Polyhierarchical

Updates & Management

- Candidate term source lists
- Updates 3 x per year
- Backposting of terms

Emtree content

Content: terminology that can be used to index

	Term types	e.g.
	Drugs	paracetamol
	Drug trade names and lab codes	tylenol, ‘mln 128’
	CASRNs	1224844-38-5
	Disease terms	headache
	Device terms	‘hancock valve prosthesis’
	Medical terms Check tags	‘self medication’ ‘human’, ‘clinical trial’

Emtree content: faceted structure

A	anatomical concepts	3,835
B	organisms	9,584
C	diseases	9,500
D	chemicals and drugs	32,447
E	procedures, parameters and devices	11,737
G	biological functions	6,553
H	chemical, physical and mathematical phenomena	1,424
I	society and environment	3,381
J	types of article or study	343
K	geographic names	541
L	groups by age and sex	204
M	named groups of persons	1,129
N	healthcare concepts	942
Q	biomedical disciplines, science and art	447
	Total for all 14 facets	**82,067**

Emtree content: faceted structure

A	anatomical concepts	3,835
B	organisms	9,584
C	diseases	9,500
D	chemicals and drugs	32,447
E	procedures, parameters and devices	11,737
G	biological functions	6,553
H	chemical, physical and mathematical phenomena	1,424
I	society and environment	3,381
J	types of article or study	343
K	geographic names	541
L	groups by age and sex	204
M	named groups of persons	1,129
N	healthcare concepts	942
Q	biomedical disciplines, science and art	447
	Total for all 14 facets	**82,067**

Emtree structure

Synonyms for taxonomy-supported searching

Emtree is rich in synonyms



Synonyms can originate from:

Alternative spelling: aspirin, aspirine

Alternative naming: ‘myocardial infarction’/‘heart attack’

MeSH terms: ‘Shock, Cardiogenic’

Chemical names: ‘2 acetoxybenzoic acid’

Trade names and laboratory codes

Indexing and searching with Emtree: mapping

- In Emtree, synonyms are linked to a preferred term
- Emtree controls what the preferred term is that will appear in the Embase index
- Synonyms or concepts in the original texts are ‘translated’ (mapped) to Emtree preferred terms



Indexing and searching with Emtree: mapping

- The link between synonyms and preferred terms can also be used while searching in Embase
- Synonyms can be used for searching, no need to know what terminology was in the original document



Indexing and searching with Emtree: mapping

Mapping means that Embase searchers get the same results regardless of which term they use and regardless of how the concept was named in the original document



Without taxonomy support…



Searching without taxonomy support

Without the connection between terms and synonyms, retrieval of information is dependent on the terminology that is used in the document and also on the terminology used to retrieve the information



A special type of synonyms: trade names

Device Tradenames	Aerolizer (Novartis, Switzerland), Genuair (Almirall, Spain)
Drug Tradenames	foradil (Novartis, Switzerland)
Device Manufacturers	Almirall (Spain), Novartis (Switzerland)
Drug Manufacturers	Novartis (Switzerland)
CAS Registry Numbers	aclidinium bromide (320345-99-1) formoterol fumarate (43229-80-7) salbutamol (18559-94-9, 35763-26-9)
Clinical Trial Numbers	ClinicalTrials.gov (NCT01120093)

Emtree structure

Polyhierarchy for taxonomy-supported searching

Emtree structure

The hierarchy of terms defines the context

Drugs can be classified via different routes:

- Drug class:
  - therapeutic use
  - system affected
  - mechanism of action
- Pharmacological activity
- Chemical structure



Make use of the Emtree structure: explosion searching





Check tags

Check tags

5.3.2 Check tags

Check tags comprise about 50 terms including most Item types (see Section 5.2), study types and age groups (see Appendix 2) whose definitions are described by scope notes. Check tags are assigned using a check list to ensure the highest possible consistency of indexing.

Category	Examples
item types	article, review, letter, erratum, conference abstract
human study types	human, major clinical study, case report, human experiment, human cell
animal study types	nonhuman, animal model, animal experiment, animal cell
sex and age	male, female, newborn, child, adolescent, aged
clinical trials and EBM	randomized controlled trial, meta analysis, double blind procedure, systematic review, phase III clinical trial

http://supportcontent.elsevier.com/Support%20Hub/Embase/Files%20&%20Attachements/4683-Embase%20indexing%20guide%202015.pdf

Check tags have scope notes

randomized controlled trial	Used for original reports of clinical trials using a control group (e.g. placebo, sham or no treatment, standard intervention) for comparison with the experimental intervention, with random allocation of subjects to experimental and control groups
major clinical study	Used for original items reporting clinical work on greater than 50 patients

Contents lists available at SciVerse ScienceDirect

Pulmonary Pharmacology & Therapeutics

journal homepage: www.elsevier.com/locate/ypupt

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

D. Singh [a,*], H. Magnussen [b], A. Kirsten [b], S. Mindt [c], C. Caracta [d], B. Seoane [e], D. Jarreta [e], E. Garcia Gil [e]

[a] University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, Langley Building, Southmoor Road, Manchester M23 9QZ, UK
[b] Pulmonary Research Institute at Hospital Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany
[c] Klinische Forschung Hamburg GmbH, Hoheluftchaussee 18, 20253 Hamburg, Germany
[d] Forest Research Institute, Harborside Financial Center, Jersey City, NJ 07311, USA
[e] Almirall R&D Centre, Ronda General Mitre 151, 08022 Barcelona, Spain

ARTICLE INFO

Article history:
Received 14 December 2011
Received in revised form
27 March 2012
Accepted 29 March 2012

Keywords:
Aclidinium
Bronchodilation
COPD
Phase II
Twice-daily

ABSTRACT

This Phase IIb, double-blind, double-dummy, placebo- and active-comparator-controlled crossover study (ClinicalTrials.gov identifier: NCT01120093) assessed efficacy and safety of three doses of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease. Patients were randomised to one of five treatment sequences each consisting of twice-daily (BID) aclidinium 100 μg, 200 μg, 400 μg (via Genuair®*), formoterol 12 μg (via Aerolizer®) and matched placebo for 7 days, with a 5- to 9-day washout period. Primary endpoint was mean change from baseline in forced expiratory volume in 1 s (FEV_1) normalised area under the curve $(AUC)_{0-12}$ on Day 7. Secondary endpoints were: change from baseline in FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24} and morning pre-dose FEV_1 on Day 7. Adverse events were monitored throughout the study. Of 79 randomised patients, 68 (86.1%) completed the study. After 7 days of treatment, aclidinium and formoterol produced statistically significantly greater changes from baseline in FEV_1 normalised AUC_{0-12} vs placebo ($p < 0.0001$). FEV_1 normalised AUC_{12-24}, FEV_1 normalised AUC_{0-24}, and morning pre-dose FEV_1 were also statistically significantly greater with all aclidinium doses vs placebo ($p < 0.0001$). Improvements in primary and

Using check tags in searches

- Check tags are consistently indexed so they can be found in the index
- Embase.com has pre-defined filters or limits to refine search results based on indexed check tags



Emtree updates & management

Candidate terms and backposting

Emtree management and backposting

- New concepts are found continuously and Emtree is updated 3 times per year to make new terminology available for indexing
- What is done during updates and where does new terminology come from?

Sources for new Emtree terms

– Candidate terms from literature, “caught” during the indexing process
– Active screening for new drugs marketed by top 25 Pharma and medical devices marketed by top medical device companies
– FDA/EMA approvals and WHO issued International Nonproprietary Names
– MeSH terms
– Focus projects, customer requests/internal requests

https://www.elsevier.com/solutions/embase-biomedical-research/embase-coverage-and-content

Candidate terms

Candidate terms can be indexed

Candidate terms can be searched for in the index

Indexed candidate terms are accompanied by:

- A broader Emtree that covers the concept
- The term ‘unclassified drug’ with drug candidate terms



Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) Inhibitor restricted to the intestinal lumen, for the treatment of diabetes

Goodwin N.C., Ding Z.-M., Harrison B.A., Strobel E.D., Harris A.L., Smith M., Thompson A.Y., Xiong W., Mseeh F., Bruce D.J., Diaz D., Gopinathan S., Li L., O'Neill E., Thiel M., Wilson A.G.E., Carson K.G., Powell D.R., Rawlins D.B.

Journal of Medicinal Chemistry 2017 **60:2** (710-721)

Go to publisher for the full text

Abstract

The increasing number of people afflicted with diabetes throughout the world is a major health issue. Inhibitors of the sodiumdependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patents. Herein we report the discovery of LX2761, a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.
© 2017 American Chemical Society.

Drug Terms open all drug terms

lx 2761, **sodium glucose cotransporter inhibitor**, unclassified drug

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

Accepted manuscript posted online 2 November 2009, doi: 10.1128/AAC.00842-09
Antimicrob. Agents Chemother. January 2010 vol. 54 no. 1 254-258

Sherene Min[1], Ivy Song[1], Julie Borland[1], Shuguang Chen[1], Yu Lou[1], Tamio Fujiwara[2] and Stephen C. Piscitelli[1,*]

Author Affiliations

ABSTRACT

S/GSK1349572 is a novel integrase inhibitor with potent *in vitro* anti-HIV activity, an *in vitro* resistance profile different from those of other integrase inhibitors, and favorable preclinical safety and pharmacokinetics (PK). Randomized, double-blind, placebo-controlled single-dose and multiple-dose, dose escalation studies evaluated the PK, safety, and tolerability of S/GSK1349572 for healthy subjects. In the single-dose study, two cohorts of 10 subjects each (8 active, 2 receiving placebo) received suspension doses of 2, 5, 10, 25, 50, and 100 mg in an alternating panel design. In the multiple-dose study, three cohorts of 10 subjects each (8 active, 2 receiving placebo) received suspension doses of 10, 25, and 50 mg once daily for 10 days. A cytochrome P450 3A (CYP3A) substudy with

In literature it usually starts with a laboratory code



Current Opinion in HIV and AIDS
Issue: Volume 4(6), November 2009, p 518–523
Copyright: © 2009 Lippincott Williams & Wilkins, Inc.
Publication Type: [Salvage therapy: Edited by Christine Katlar
DOI: 10.1097/COH.0b013e328331b526
ISSN: 1746-630X
Accession: 01222929-200911000-00011
Keywords: elvitegravir, HIV, integrase inhibitors, raltegravir, th

Introduction

Integrase inhibitors belong to a new class of antiretroviral compounds (integrase strand transfer inhibitors, InSTIs) that offer an attractive alternative to other antiretrovirals in the setting of salvage therapy and in treatment-naive patients, firstly and most importantly, because of their different target enzyme and, as a consequence, potent activity against virus strains that carry resistance mutations against drugs from other classes. Raltegravir (RAL) was the first drug in this class to be approved by the United States Food and Drug Administration (FDA) for use in highly treatment-experienced HIV-1-infected patients in October 2007. In January 2009, the FDA granted traditional approval for the 400 mg RAL tablets (Isentress; Merck and Company, Whitehouse Station, New Jersey, USA) for HIV-1 treatment in treatment-experienced individuals in combination with other antiretrovirals. In July 2009, the FDA extended approval for Isentress for the treatment of treatment-naive patients. A second drug in this class, elvitegravir, is in the late stages of clinical development and currently in phase III clinical trials. Other InSTIs, for example, MK-2048 (Merck, NJ, USA) and GSK1349572 (GlaxoSmithKline, NC, USA) (GlaxoSmithKline, London, UK) are in early clinical development.

Candidate terms can be added to Emtree

In the case of drugs, new entities may initially be designated as laboratory codes and only later using chemical names, trade names or generic names. In Emtree, the preferred term is always the generic name, if it is available. When older terms are replaced in Emtree by newer terms, articles with the older index terms can be *backposted* so that the old terms are replaced by the new index terms. This procedure is used on Embase.com, but is not available on all platforms.

Adding to Emtree: synonyms and structure

Terminology searched for:
Generic name
IUPAC chemical name
Laboratory code/trade name

dolutegravir

1,074 records found

History

This term was added to Emtree in 2012

Synonyms

3, 4, 6, 9, 9a, 10 hexahydro 5 hydroxy 4 methyl 6, 10 dioxo 2h 1 oxa 4a, 8a diazaanthracene 7 carboxylic acid 2, 4 difluorobenzylamide; 5 hydroxy 4 methyl 6, 10 dioxo 3, 4, 6, 9, 9a, 10 hexahydro 2h 1 oxa 4a, 8a diazaanthracene 7 carboxylic acid 2, 4 difluorobenzylamide; dolutegravir sodium; dolutegravir sodium monohydrate; gsk 1349572; gsk 1349572a; gsk 572; gsk1349572; gsk1349572a; gsk572; n (2, 4 difluorobenzyl) 3, 4, 6, 8, 12, 12a hexahydro 7 hydroxy 4 methyl 6, 8 dioxo 2h pyrido [1', 2':4, 5] pyrazino [2, 1 b] [1, 3] oxazine 9 carboxamide; n [(2, 4 difluorophenyl) methyl] 7 hydroxy 4 methyl 6, 8 dioxo 3, 4, 6, 8, 12, 12a hexahydro 2h pyrido [1', 2':4, 5] pyrazino [2, 1 b] [1, 3] oxazine 9 carboxamide; s 1349572; s 349572; s gsk 1349572; s gsk1349572; s-349572; s1349572; s349572; sodium 5 hydroxy 4 methyl 6, 10 dioxo 3, 4, 6, 9, 9a, 10 hexahydro 2h 1 oxa 4a, 8a diazaanthracene 7 carboxylic acid 2, 4 difluorobenzylamide; tivicay

CAS Registry Numbers

1051375-16-6; 1051375-19-9; 1172581-47-3

Drugs can be classified via different routes:

- Drug class
  - therapeutic use
  - system affected
  - mechanism of action
- Pharmacological activity
- Chemical structure



Backposting

When older terms are replaced in Emtree by newer terms, articles with the older index terms can be **backposted** so that the **old terms are replaced by the new index terms**. This procedure is used on Embase.com, but is not available on all platforms.



Current Opinion in HIV and AIDS
Issue: Volume 4(6), November 2009, p 518–523

Publication Type: [Salvage therapy: Edited by Christine Katlama and Paul S
DOI: 10.1097/COH.0b013e328331b526
ISSN: 1746-630X
Accession: 01222929-200911000-00011
Keywords: elvitegravir, HIV, integrase inhibitors, raltegravir, therapy

Introduction

Integrase inhibitors belong to a new class of antiretroviral compounds (integrase strand transfer inhibitors, InSTIs) that offer an attractive alternative to other antiretrovirals in the setting of salvage therapy and in treatment-naive patients, firstly and most importantly, because of their different target enzyme and, as a consequence, potent activity against virus strains that carry resistance mutations against drugs from other classes. Raltegravir (RAL) was the first drug in this class to be approved by the United States Food and Drug Administration (FDA) for use in highly treatment-experienced HIV-1-infected patients in October 2007. In January 2009, the FDA granted traditional approval for the 400 mg RAL tablets (Isentress; Merck and Company, Whitehouse Station, New Jersey, USA) for HIV-1 treatment in treatment-experienced individuals in combination with other antiretrovirals. In July 2009, the FDA extended approval for Isentress for the treatment of treatment-naive patients. A second drug in this class, elvitegravir, is in the late stages of clinical development and currently in phase III clinical trials. Other InSTIs, for example, MK-2048 (Merck, NJ, USA) and GSK1349572 (GlaxoSmithKline, NC, USA) (GlaxoSmithKline, London, UK) are in early clinical development.

Drug Terms

antivirus agent, atazanavir, efavirenz, elvitegravir, enfuvirtide, etravirine, cobicistat, dolutegravir, **integrase inhibitor** inhibitor, raltegravir, rifampicin, ritonavir, RNA directed DNA polymerase inhibitor, tipranavir, unclassified drug

Drug Tradenames	gs 9350, gsk 1349572, mk 0248

Using the knowledge

Make use of Emtree to get the best results out of Embase

Get the best out of Embase: systematic searching with Emtree

Q:

Use Embase to find reports on comparison between aspirin and clopidogrel in the treatment of thrombosis.

But don’t get too many results: limit to ‘randomized controlled trial’

A:

Understanding the principles of indexing and the structure of Emtree helps create search strategy: breakdown the question into indexing terminology

Get the best out of Embase: systematic searching with Emtree

Q:

Use Embase to find reports on **comparison** between **aspirin** and **clopidogrel** in the treatment of **thrombosis**.

But don’t get too many results: limit to ‘**randomized controlled trial**’

A:

Understanding the principles of indexing and the structure of Emtree helps create search strategy: breakdown the question into indexing terminology



PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp ▼ Add 11 synonyms

Clear field

Intervention

e.g. insulin

Comparison

e.g. placebo

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 300,651 results

11 synonyms

for thrombosis

ALL

- acute thrombosis
- arm thrombosis
- atherothrombosis
- rethrombosis
- sclerothrombosis
- thromboobliterative disease
- thromboocclusive disease
- thrombosis
- thrombosis induction
- thrombotic disease
- thrombotic occlusion

PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp + 11 synonyms:all

Clear field

Intervention

e.g. insulin

Comparison

e.g. placebo

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 396,632 results

Find best term

aspirin

- aspirin
  Use preferred term 'acetylsalicylic acid'
  187,642 records found
- aspirin bayer
  Use preferred term 'acetylsalicylic acid'
  187,642 records found
- aspirina
  Use preferred term 'acetylsalicylic acid'
  187,642 records found
- aspirine
  Use preferred term 'acetylsalicylic acid'
  187,642 records found
- aspirinine
  Use preferred term 'acetylsalicylic acid'
  187,642 records found
- aspirin lysine
  Use preferred term 'lysine acetylsalicylate'
  1,784 records found
- aspirin dipyridamole drug combination
  Use preferred term 'acetylsalicylic acid plus dipyrid...
  909 records found
- aspirin plus dipyridamole

PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp + 11 synonyms:all

Clear field

Intervention

Comparison

e.g. placebo

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 396,632 results

Find best term

aspirin

- Emtree
  - chemicals and drugs
    - agents affecting metabolism
      - enzyme inhibitor
        - oxidoreductase inhibitor
          - oxygenase inhibitor
            - prostaglandin synthase inhibitor
              - acetylsalicylic acid
    - organic compound
      - functional group
        - polyfunctional group
          - hydroxyacid
            - hydroxybenzoic acid derivative
              - salicylic acid derivative
                - acetylsalicylic acid
    - hematologic agent
      - anticoagulant agent
        - antithrombocytic agent
          - acetylsalicylic acid
    - analgesic, antiinflammatory, antirheumatic and an...
      - analgesic agent
        - antipyretic analgesic agent
          - acetylsalicylic acid
      - antiinflammatory agent
        - nonsteroid antiinflammatory agent
          - acetylsalicylic acid

PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp ▼ + 11 synonyms:all ▼

Clear field

Intervention

acetylsalicylic acid /exp ▼ Add 269 synonyms

Clear field

Comparison

e.g. placebo

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 33,145 results



PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp + 11 synonyms:all

Clear field

Intervention

acetylsalicylic acid /exp + 268 synonyms:all

Clear field

Comparison

e.g. placebo

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 34,757 results

Find best term

clopidogrel

- Emtree
  - chemicals and drugs
    - agents interacting with transmitter, hormone or dr...
      - purinergic receptor affecting agent
        - purinergic receptor blocking agent
          - purinergic P2 receptor antagonist
            - purinergic P2Y receptor antagonist
              - clopidogrel
    - organic compound
      - compounds according to chemical structure
        - hydrocarbon
          - polycyclic hydrocarbon
            - bridged bicyclo compounds
              - fused heterocyclic rings
                - fused carbon nitrogen sulf...
                  - clopidogrel
        - heterocyclic compound
          - fused heterocyclic rings
            - fused carbon nitrogen sulfur heter...
              - clopidogrel
        - bridged compound
          - bridged bicyclo compounds
            - fused heterocyclic rings
              - fused carbon nitrogen sulfur h...
                - clopidogrel
    - hematologic agent
      - anticoagulant agent
        - antithrombocytic agent
          - clopidogrel

PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp + 11 synonyms:all

Clear field

Intervention

acetylsalicylic acid /exp + 268 synonyms:all

Clear field

Comparison

clopidogrel /exp Add 26 synonyms

Clear field

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 12,593 results



PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp + 11 synonyms:all

Clear field

Intervention

acetylsalicylic acid /exp + 268 synonyms:all

Clear field

Comparison

clopidogrel /exp + 26 synonyms:all

Clear field

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 12,884 results

Find best term

rand

- Emtree
  - types of article or study
    - types of study
      - in vivo study
        - clinical study
          - clinical trial
            - controlled clinical trial
              - randomized controlled trial
      - methodology
        - evidence based practice
          - evidence based medicine
            - randomized controlled trial
      - controlled study
        - controlled clinical trial
          - randomized controlled trial

PICO Search

Note: Filling any search line is optional

Default search strategy

/mj /de /exp /br

Population

thrombosis /exp + 11 synonyms:all

Clear field

Intervention

acetylsalicylic acid /exp + 268 synonyms:all

Clear field

Comparison

clopidogrel /exp + 26 synonyms:all

Clear field

Outcome

e.g. risk

Study design (or miscellaneous)

randomized controlled trial /exp Add 8 synonyms

Clear field

Reset query Info

Show 919 results

History Save | Delete | Print view | Export | Email Combine using And Or Collapse

#1 'thrombosis'/exp OR 'acute thrombosis' OR 'arm thrombosis' OR 'atherothrombosis' OR 'rethrombosis' OR 'sclerothrombosis' OR 'thromboobliterative disease' OR 'thromboocclusive disease' OR 'thrombosis' OR 'thrombosis induction' OR 'thrombotic disease' OR 'thrombotic occlusion' AND ('acetylsalicylic acid'/exp OR '2 acetoxybenzoate' OR '2 acetoxybenzoic acid' OR '8-hour bayer' OR 'acenterine' OR 'acesal' OR 'acetan' OR 'acetard' OR 'aceticil' OR 'aceticyl' OR 'acetilum' OR 'acetonyl' OR 'acetophen' OR 'acetosal' OR 'acetosalicylic acid' OR 'acetosalin' OR 'acetosalum' OR 'acetyl salicylate' OR 'acetyl salicylic acid' OR 'acetylic salicylic acid' OR 'acetylin' OR 'acetylo' OR 'acetylo salicylic acid' OR 'acetylon' OR 'acetylosalicylic acid' OR 'acetylsal' OR 'acetylsalicyclic acid' OR 'acetylsalicyl' OR 'acetylsalicylate' OR 'acetylsalicylate strontium' OR 'acetylsalicylic acid' OR 'acetylsalicylic acid plus glycine' OR 'acetylsalicylic acid sodium salt' OR 'acetylsalicylic acid strontium salt' OR 'acetylsalycic acid' OR 'acetylsalycylic acid' OR 'acetysal' OR 'acidulatum' OR 'acidum acetyl salicylicum' OR 'acidum acetylosalicylicum' OR 'acidum acetylsalicylicum' OR 'actorin' OR 'acylpyrin' OR 'acylpyrine' OR 'acytosal' OR 'adiro' OR 'alabukun' OR 'alasil' OR 'albyl e' OR 'albyl minor' OR 'albyl-e' OR 'alka seltzer' OR 'alka-seltzer' OR 'alkaspirin' OR 'anasprin' OR 'andol' OR 'anopyrin' OR 'ansin' OR 'anthrom' OR 'aptor' OR 'arthralgyl' OR 'arthritis strength bufferin' OR 'asa akut' OR 'asa cardio' OR 'asa direk' OR 'asa effect' OR 'asa express' OR 'asa migraene' OR 'asa migrane' OR 'asa migren' OR 'asa pro' OR 'asa protect' OR 'asa ultra' OR 'asa ultra fast' OR 'asa zipp' OR 'asaa' OR 'asaa gr' OR 'asaa microactive' OR 'asaa rapida' OR 'asacard' OR 'asae' OR 'asae bruis' OR 'asae ec protect' OR 'asae fasttabs' OR 'asae protect' OR 'asaetta' OR 'asaflow' OR 'asaphen' OR 'asaphen e.c.' OR 'asapor' OR 'asatard' OR 'asawin' OR 'aspec' OR 'aspec-ec' OR 'aspent' OR 'aspergum' OR 'aspex' OR 'aspilets' OR 'aspirem' OR 'aspirgran' OR 'aspiricor' OR 'aspirin' OR 'aspirin bayer' OR 'aspirina' OR 'aspirine' OR 'aspirinine' OR 'aspirisucre' OR 'aspisol' OR 'aspo cid' OR 'aspro' OR 'aspro cardio' OR 'aspro clear' OR 'asproflash' OR 'asrina' OR 'asrivo' OR 'asta' OR 'asteric' OR 'asteric acid' OR 'astrix' OR 'bamyl' OR 'bayaspirina' OR 'bayer aspirin' OR 'bayer aspirin cardio' OR 'bayer extra strength aspirin for migraine pain' OR 'bebesan' OR 'biprin' OR 'bokey' OR 'boxazin' OR 'breoprin' OR 'buffered aspirin' OR 'bufferin' OR 'bufferin low dose' OR 'cafenol' OR 'caprin (acetylsalicylic acid)' OR 'caprin (aspirin)' OR 'cardioasa' OR 'cardioasae' OR 'cardioaspirina' OR 'cardioflow (acetylsalicylic acid)' OR 'cartia' OR 'caspirin' OR 'catalgine' OR 'catalgix' OR 'cemerit' OR 'cemirit' OR 'claradin' OR 'claragine' OR 'colfarit' OR 'comoprin' OR 'contrheuma' OR 'contrheuma retard' OR 'darosal' OR 'depot aspirin' OR 'dispirin' OR 'dolean' OR 'durlaza' OR 'dusil' OR 'easprin' OR 'ecasil' OR 'ecosprin' OR 'ecotrin' OR 'ecotrin 650' OR 'egalgic' OR 'emocin' OR 'empirin' OR 'encaprin' OR 'encine em' OR 'endosprin' OR 'entaprin' OR 'entericin' OR 'enteroprin' OR 'enterosarine' OR 'enterospirine' OR 'entrophen' OR 'eskotrin' OR 'euthermine' OR 'extren' OR 'flamasacard' OR 'genasprin' OR 'globentyl' OR 'godamed' OR 'gotosan' OR 'helicon' OR 'herz ass' OR 'hjertemagnyl' OR 'idotyl' OR 'infatabs a' OR 'istopirin' OR 'istopyrine' OR 'ivepirine' OR 'juvepirine' OR 'keypo' OR 'kilios' OR 'kinderaspirin' OR 'magnecyl brus' OR 'magnyl dak' OR 'mcn r 358' OR 'measurin' OR 'mejoral' OR 'melabon' OR 'micristin' OR 'micropyrin' OR 'migrasaa' OR 'mikristin' OR 'miniasal' OR 'mycristin' OR 'naspro' OR 'novasen' OR 'nu seal' OR 'nu-seals' OR 'nu-seals asa' OR 'nuseals' OR 'ortho acetoxybenzoate' OR 'ortho acetoxybenzoic acid' OR 'ortho acetyloxybenzoate' OR 'ortho acetyloxybenzoic acid' OR 'ostoprin' OR 'pancemol' OR 'para acetylsalicylic acid' OR 'paracin' OR 'paynocil' OR 'pengo' OR 'platet 300 cleartab' OR 'plewin' OR 'polopiryna' OR 'premaspin' OR 'primaspan' OR 'proprin' OR 'pyronoval' OR 'reumyl' OR 'rhodine' OR 'rhonal' OR 'rhonal for children' OR 'ronal' OR 'salacetin' OR 'salacetogen' OR 'saletin' OR 'salisalido' OR 'salospir' OR 'sargepirine' OR 'sedergine' OR 'sedergine forte' OR 'slow release aspirin' OR 'sodium acetylsalicylate' OR 'sodium bicarbonate acetyl salicylate' OR 'sodium bicarbonate acetylsalicylate' OR 'soldral' OR 'solpyron' OR 'solucetyl' OR 'solupsa' OR 'spren' OR 'super tru' OR 'tapal' OR 'temagin' OR 'tevapirin' OR 'th 2152' OR 'thrombo-aspilets' OR 'toldex retard' OR 'treupahlin' OR 'treuphalin' OR 'tromalyt' OR 'tromcor' OR 'turivital' OR 'verin' OR 'vitalink' OR 'xaxa' OR 'ysp aspirin' OR 'zero-order release' OR 'zorprin') AND ('clopidogrel'/exp OR '2 (2 chlorophenyl) 2 (4, 5, 6, 7 tetrahydrothieno [3, 2 c] pyridin 5 yl) acetic acid methyl ester' OR 'clopidogrel' OR 'clopidogrel besilate' OR 'clopidogrel besylate' OR 'clopidogrel bisulfate' OR 'clopidogrel bisulphate' OR 'clopidogrel bms' OR 'clopidogrel hcs' OR 'clopidogrel hydrobromide' OR 'clopidogrel hydrochloride' OR 'clopidogrel hydrogen sulfate' OR 'clopidogrel hydrogen sulphate' OR 'clopidogrel winthrop' OR 'clopilet' OR 'grepid' OR 'iscover' OR 'pcr 4099' OR 'pcr4099' OR 'plavix' OR 'sr 25989' OR 'sr 25990c' OR 'sr25989' OR 'sr25990c' OR 'zopya' OR 'zylagren' OR 'zyllt') AND 'randomized controlled trial'/exp 919

919 results for search #1 Set email alert Set RSS feed Search details

Results View | Print | Export | Email | Order | Add to Clipboard 1 — 25

Select number of items Selected: 0 (clear) Show all abstracts | Sort by: Relevance Publication Year Entry Date

1 Impact of ticagrelor and aspirin versus clopidogrel and aspirin in symptomatic patients with peripheral arterial disease (PAD): Thrombus burden assessed by intravascular optical coherence tomography
Yang X., Leesar M., Ahmed H., Lendel V., Cawich I., Prasad A., Oglesby M., Taylor H., Feldman M.D., Cilingiroglu M.
Catheterization and Cardiovascular Interventions 2017 89 *Supplement 2* (S101-S102)
Embase Abstract Index Terms View Full Text

2 Surgical or transcatheter aortic-valve replacement in intermediate-risk patients
Reardon M.J., Van Mieghem N.M., Popma J.J., Kleiman N.S., Sondergaard L., Mumtaz M., Adams D.H., Deeb G.M., Maini B., Gada H., Chetcuti S., Gleason T., Heiser J., Lange R., Merhi W., Oh J.K., Olsen P.S., Piazza N., Williams M., Windecker S., Yakubov S.J., Grube E., Makkar R., Lee J.S., Conte J., Vang E., Nguyen H., Chang Y., Muggiin A.S., Serruys P.W.J.C., Kappetein A.P.
New England Journal of Medicine 2017 376:14 (1321-1331)
Embase MEDLINE Abstract Index Terms View Full Text

3 Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
Hoshi T., Sato A., Nogami A., Gosho M., Aonuma K.
Journal of Cardiology 2017 69:4 (648-651)
Embase Abstract Index Terms View Full Text

919 results for search #1 Set email alert Set RSS feed Search details

Results View | Print | Export | Email | Order | Add to Clipboard 1 — 25

Select number of items Selected: 0 (clear) Show all abstracts | Sort by: Relevance Publication Year Entry Date

1 Impact of ticagrelor and aspirin versus clopidogrel and aspirin in symptomatic patients with peripheral arterial disease (PAD): Thrombus burden assessed by intravascular optical coherence tomography

Yang X., Leesar M., Ahmed H., Lendel V., Cawich I., Prasad A., Oglesby M., Taylor H., Feldman M.D., Cilingiroglu M.

Catheterization and Cardiovascular Interventions 2017 89 *Supplement 2* (S101-S102)

Embase Abstract Index Terms View Full Text

2 Surgical or transcatheter aortic-valve replacement in intermediate-risk patients

Reardon M.J., Van Mieghem N.M., Popma J.J., Kleiman N.S., Sondergaard L., Mumtaz M., Adams D.H., Deeb G.M., Maini B., Gada H., Chetcuti S., Gleason T., Heiser J., Lange R., Merhi W., Oh J.K., Olsen P.S., Piazza N., Williams M., Windecker S., Yakubov S.J., Grube E., Makkar R., Lee J.S., Conte J., Vang E., Nguyen H., Chang Y., Muggiln A.S., Serruys P.W.J.C., Kappetein A.P.

New England Journal of Medicine 2017 376:14 (1321-1331)

Embase MEDLINE Abstract Index Terms View Full Text

Drug Terms

acetylsalicylic acid, clopidogrel

Disease Terms

acute kidney failure, **aorta stenosis**, aorta valve regurgitation, atrial fibrillation, cerebrovascular accident, self expanding aorta valve prosthesis, thrombosis

Device Terms

aorta valve prosthesis

Other Terms

age distribution, aged, **aorta valve replacement**, article, blood transfusion, clinical effectiveness, controlled study, death, disease severity, female, human, **intermediate risk patient**, intermethod comparison, major clinical study, male, multicenter study, outcome assessment, pacemaker implantation, patient safety, postoperative period, randomized controlled trial, surgical risk, **transcatheter aortic valve implantation**

3 Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention

Hoshi T., Sato A., Nozami A., Gosho M., Aonuma K.

Thank you for your attention

Questions?